A number of clinical trials are currently underway to explore the therapeutic efficacy of BDFs, particularly focusing on the inhibition of RANKL and Sclerostin in the management of osteoporosis as well as various other bone disorders. The gene discussed is TNFSF11; the disease is osteoporosis.